FARMINGDALE, NY — January 2026 — Enzo Life Sciences today announced the launch of its next-generation AMPIVIEW® RNA probe platform, delivering significant advances in sensitivity, specificity, and multiplexing capability for spatial transcriptomics and in-situ hybridization applications.

The new platform builds on Enzo's decades of expertise in nucleic acid labeling and detection technology, incorporating proprietary signal amplification chemistry that enables researchers to detect low-abundance transcripts with exceptional clarity in tissue and cell preparations.

Platform Advances

• Up to 10x improvement in signal-to-noise ratio compared to previous generation
• Multiplexing of up to 12 targets simultaneously in a single tissue section
• Compatible with FFPE, fresh-frozen, and whole-mount tissue preparations
• Custom probe design service with 5-day turnaround for validated probes
• Complete workflow kits including all buffers, detection reagents, and counterstains

Enabling Spatial Biology

"Spatial biology is transforming our understanding of tissue architecture and disease pathology," said the Head of R&D. "The next-generation AMPIVIEW platform gives researchers the tools they need to visualize gene expression in its native spatial context, opening new avenues for biomarker discovery, drug target validation, and diagnostic development."

The platform is designed for use in a wide range of applications including cancer research, neuroscience, immunology, and developmental biology. Researchers can select from Enzo's growing catalog of pre-validated probes or request custom probe design targeting any gene of interest.

Availability

The next-generation AMPIVIEW platform is available for order immediately through Enzo's global distribution network. Custom probe design services are available with standard 5-business-day turnaround.